

Enzyvitands: evolvable biosynthetic and colorimetric chalices

Raphael Gobat^a, Bing Zhang^{a,1}, Thibaud Rossel^{b,2,3}

^a Biozentrum, University of Basel,
Klingelbergstrasse 50/70, Basel, 4056, Switzerland

^b Gymnase français de Bienne,
Rue du débarcadère 8, 2503, Bienne, Switzerland

Abstract The literature is constalted with a wide variety of chemosensors against a plethora of analytes. [22, 26, 31, 30, 3, 5, 29, 59, 60, 4] This seminal library is used to inspire chemists to improve them using chemical synthesis. However, their optimization via chemical processes is a difficult task which takes time without the guarantee of final success. [48] We show here that combinatorial chemistry [23], the use of first and second coordination spheres interactions and the displacement of indicators united within a protein cavity [6] offers an easy-to-assemble colorimetric bio-chemical sensor that we call: Enzyvitand. It consists only of commercial chemicals. This colorimetric sensor is highly modular, cheap and evolvable. Its X-ray structure reveals the composition of its active site. This allows to design it rationally for the recognition of dopamine with the naked eye. Our bio-sensor therefore resembles a biological receptor for the recognition of neurotransmitters. Its immediate high adaptability and ability to be evolved can be useful for the selective detection of a wide variety of analytes going from small molecules to microorganisms. This discovery therefore makes it possible to dream of new biotechnological or new immunotherapeutic applications. [12, 13, 7, 9, 10, 11, 41, 42, 43]

1 Introduction

The literature abounds with descriptions of chemo-sensors for the detection of a wide variety of analytes. [22, 26, 31, 30, 3, 5, 29, 28] In particular be made of: cyclophanes [44], crown ethers [51, 61], cryptands [45], cavitands [46, 47], calix[n]arenes [52], calix[n]pyrroles [49], cucurbit[n]uril [50], cyclodextrines [57, 58], pinwheels [53, 54], dendrimers, [55] MOFS [56], or boronic acids [26, 31, 3, 5, 29, 4]. All these sensors take advantage of the first coordination sphere to capture analytes. None of them are easily synthetically optimized. Each requires synthesis steps that take time, are tedious and do not guarantee success. Based on this, by observing Nature more closely, we realize that bio-receptors such as membrane receptors [17, 27] are perfectly designed for the recognition of analytes. [27] Mention may in particular be made of membrane receptors for the recognition of neurotransmitters, for example dopaminergic receptors. [27, 15] These optimized receptors [1, 2] take advantage of the second coordination sphere given by a proteic environment for selective recognition. The active recognition site is decorated with amino acids that interact with the analyte to hold it captive. Dopamine, for example, is locked in the active site through its catechol moiety via a serine microdomain. Whereas, the protonated amine of dopamine at physiological pH is locked with an ionic bond through the interaction with an aspartate conserved in all biogenic amine GPCRs. [67, 68]

¹E-mail: bing.zhang@unibas.ch

²Corresponding author.

³E-mail: thibaud.rossel@emsp.gfbienne.ch

Therefore, inspired by chemical and biological sensors, we wanted to merge the best of both worlds to make a novel type of sensor. A sensor optimized by the first and second sphere of coordination for the exquisite recognition of analytes. In addition, we wanted to add optical properties to it, in particular a color change during detection by using an indicator displacement as well as evolvable features.

We chose a protein with a deep cavity. [6] We then redesigned its active site by introducing a ligand into it. This ligand carries a functional group and is anchored supramolecularly to the protein. On this functional group we added a colored indicator. When an analyte enters the active site, it attaches to the functional group and displaces the indicator. The change in color indicates interactions between the active site and the analyte. The second sphere of coordination acts as a screen. It selects the access to the analyte at the active site. More specifically, we have incorporated into the carbonic anhydrase, boronic acids [26, 31, 3, 29] coordinated with indicators. These colorimetric sensors were screened in the presence of neurotransmitters.

The results show that we have obtained a highly selective, cheap and easy to assemble dopamine sensor mimicking biological membrane receptors. Such a discovery allows us to imagine optimizations taking advantage of the broad possibilities such as the ligand and its functional group, the indicators, the protein by mutation, the pH, the temperature and or the concentration of the reactions, etc. This can lead to dynamic combinatorial chemistry [23], high throughput screening [24] and optimization processes via directed evolution protocols [25] using for example machine learning [38]. The immediate high adaptability and ability of our sensor to be evolved can be useful for the selective detection of a wide variety of analytes going from small molecules to microorganisms. This discovery therefore makes it possible to dream of new biotechnological or new immunotherapeutic applications [12, 13, 7, 9, 10, 11, 41, 42, 43] We show, proof of principle, that guided through the crystal structure of our receptor, we can create a cheap, easy to assemble, colorimetric biosensor for the selective naked-eye detection of dopamine which mimics a dopaminergic receptor.

2 Methods

2.1 First coordination sphere detection

Dissolving 4-sulfamoyl(phenyl)boronic acid (**1** *p*-BA, 250 μ M) and pyrocatechol violet (**2** PCV, 250 μ M) in 2-[4-(2-hydroxyethyl)-1 piperazinyl]ethanesulfonic acid (HEPES, 100 mM, pH=7.4) in a 1:1 mixture formed (*p*-BAPCV, 250 μ M), which is water-soluble and orange-red at working micromolar concentrations (see Figure 1). By homology with other reported arylboronic acid described in literature, we hypothesized that *p*-BAPCV could be formed and used to assemble a receptor for the naked-eye detection of various vicinal diols such as carbohydrates as described for **17** (D)-fructose [26] (See Figure 3) or catechols [22] such as **9** dopamine (see Figure 1 and Figure 3).

As anticipated *p*-BAPCV can detect visually and spectrophotometrically both **17** (D)-Fructose and **9** dopamine with a concomitant color change using an indicator displacement assay (IDA) (see Figure 1). We determined the association constant of *p*-BAPCV with **9** dopamine using an indicator displacement assay and we obtained a $K_{ass} = 2.12 \cdot 10^6 \text{ M}^{-1}$ (see Table 1). [40] [26] Screening of various pHs ranging from pH = 5 to pH = 8 showed the best discrimination at pH = 7.4 as reported in other publications. [26, 5]

2.1.1 Chemical diversity

To generate diversity in the composition of our sensors, we tested and used chemical optimization strategies. In such, combining two different sulfonamides boronic acids (**1** *p*-BA or **2** *m*-BA) with catechol based indicators (**3** PCV or **4** ARS) yielded four potential sensors for the detection of analytes. Of the four sensors tested only **1** *p*-BA was able to coordinate either **3** PCV or **4** ARS forming: *p*-BAPCV and *p*-BAARS. **2** *m*-BA did not react with both indicators suggesting that the position of the boronic acid in the aryl-sulphonamid moiety plays a key role in the coordination process of the indicator. With both *p*-BAPCV and *p*-BAARS in hands, we tested the two chemical variants with **17** (D)-Fructose for recognition and both offered an indicator displacement assay allowing detection of the analyte and showing no special




Table 1. Association constants of systems

System	K_{ass} [M^{-1}]
<i>p</i> -BA with PCV	$1.36 \cdot 10^5$
<i>p</i> -BAPCV with dopamine	$2.12 \cdot 10^6$
<i>p</i> -BAPCV with bCA	$2.08 \cdot 10^5$
<i>p</i> -BAPCV \subset bCA with dopamine	xxxxxxx

selectivity in the recognition process (see Figure 3). For the continuation of our study, we therefore selected *p*-BAPCV and *p*-BAARS.

2.2 Second coordination sphere detection

The catalytic Zn-active site present at the bottom of a deep hydrophobic funnel-shaped cavity of carbonic anhydrase endows high affinity for para-substituted aryl sulphonamids. [6] We thus speculated that upon tethering an aryl-sulfonamides boronic acid conjugated with an indicator may allow to anchor a recognition site within **5** bCA allowing an exchange between the indicator and selected molecules of choice (see Figure 1). In a first time, in order to confirm our hypothesis, we assembled the arylboronic acid **1** *p*-BA (250 μ M) and **2** PCV (250 μ M) in HEPES 100 mM, pH = 7.4 and formed *p*-BAPCV (λ_{max} = 465 nm) which is orange colour in a 1:1 mixture. We performed a titration of **1** with **2** in order to determine the binding constant of the host-guest receptor and obtained a $K_{ass} = 1.36 \cdot 10^5 M^{-1}$ (see Table 1) with a 1:1 association.

In a second time, we added **5** bCA (1 eq.) to the 1:1 mix of *p*-BAPCV or *p*-BAARS (250 μ M in HEPES pH = 7.4). For *p*-BAPCV \subset bCA, a bathochromic change in colour appeared immediately after the addition of the protein (see Figure 1). The orange solution (λ_{max} of = 495 nm) of *p*-BAPCV turned intense pink with a λ_{max} of = 525 nm (see Figures 1 and 3). Titration of **5** bCA with *p*-BAPCV shows a bathochromic shift in color from 495 nm to 525 nm and a Job Plot titration confirms a 1:1 association of the bio-receptor (see supporting information) and an association constant of $3.60 \cdot 10^5 M^{-1}$ (see Table 1). Same conclusions were observed for *p*-BAARS \subset where the shift in color is from 480 nm for *p*-BAARS to 485 nm for *p*-BAARS \subset however less pronounced than for *p*-BAPCV \subset bCA. The change in color confirms that the assembled orange colored *p*-BAPCV enters the protein. More interestingly, the order of the addition of **1** *p*-BA, **3** PCV and the protein **5** bCA didn't play any critical role. One can either form *p*-BAPCV before addition to **5** bCA or add *p*-BAPCV to the protein and add the indicator such as **3** PCV in a second time for coordination to *p*-BAPCV (see Figures 1 and 3) leading to an *indicator uptake-assay* which is known to improve the sensitivity of the assay compared to the displacement. [28] It suggests that CA can be used as a boronic proteic based platform for the recognition of analytes opening new routes for therapeutic proteins against catecholamines and that **3** PCV can be used as a sensor to probe the recognition of analytes coordinated to the boronic acid inside the active site of the protein.

2.2.1 Proteic diversity

In order to increase the diversity and induce selectivity in our sensors, we combined the two constructs *p*-BAPCV and *p*-BAARS with two variants of carbonic anhydrase such as **5** bCA (bovine carbonic anhydrase) and **6** hCAII (human carbonic anhydrase). The combination offered a four possibilities matrix ready to be screened with analytes; *p*-BAPCV \subset bCA, *p*-BAPCV \subset hCAII, *p*-BAARS \subset bCA, *p*-BAARS \subset hCAII.

2.3 Indicator displacement assay

We then tested our matrix of four sensors; *p*-BAPCV \subset bCA, *p*-BAPCV \subset hCAII, *p*-BAARS \subset bCA, *p*-BAARS \subset hCAII for the detection of **17** (D)-fructose through an IDA since recognition is described in literature outside a second coordination sphere. [26] The detection was not possible even in the presence of a large excess of **17** (D)-fructose (100 eq. of fructose compared to the proteic bio-conjugates) (see Figure 3) thus suggesting that the cavity of the protein prevents the entry of the sugar compared to the free assembled ligand-boronic complex *p*-BAPCV. In order to confirm the supra-molecular assembly, we performed a

titration of the complex *p*-BAARS and *p*-BAPCV with a 1 (250 μ M) to 0.1 (25 μ M) ratio of *p*-BAARS and *p*-BAPCV versus **5** bCA and an excess of **17** (D)-fructose (100 eq., 0.025 M) (see Figure 1). Color change outside the protein was observed both for **3** ARS and **4** PCV as indicators confirming that the excess of *p*-BAARS and *p*-BAPCV (250 μ M) outside the protein reacts with **17** (D)-fructose (see Figures 1 and 3). As a consequence and in order to explore further the detection ability of our construct, we decided to investigate various analytes for recognition.

2.4 Crystal structure of the bio-sensor

In order to do so and predict further the interactions of potential analytes with our biosensor, we set out to crystallize it. hCAII Crystals were obtained using sitting-drop vapor diffusion at 20 °C in 24-well plates as described [66]. plate-shaped crystals matured within one week in reservoir containing 2.6 M (NH₄)₂SO₄, 50 mM Tris-HCl pH 8.5. **1** *p*-BA was soaked inside the enzyme sequentially. The soaked crystals were incubated at 20 °C for 2 h and harvested by flash freezing in liquid nitrogen. Diffraction data was collected at the beamline X06SA at the Swiss Light Source (SLS, Villigen). Datasets were processed and merged with XDS [62]. The phases were solved by molecular replacement using Phaser [63] with hCAII structure (PDB code: 3ZP9) as the search model. The model building was done in COOT [64] and refined with Phenix [65] (X-ray data and refinement statistics are given in the supporting information). The obtained crystal structure (See Figure 2 **A** and **B**) was compared with the reported structure of hCAII with **18** 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylsulfamide [7, 9, 17, 32, 20, 27, 39, 14, 42, 57] (PDB code: 3MNU, see Figure 2). Attempt to obtain crystal structure of *p*-BA \subset hCAII in conjugation with **3** PCV or **9** dopamine was not possible probably due to disruption of crystals in the soaking process.

2.5 Screening of analytes

With the obtained crystal structure (PDB code: 6XVH) in hands (see Figure 2) we reasoned that molecules with a geometric similarity with the cavity should enter more easily the pocket of CA compared to **17** (D)-fructose. [26] In so, we were particularly interested in the close lying aminoacids to the boronic acids moiety such as: T-200, L-198, F-131, V-135, C-206. F-131 and especially F-131 that could interact with potential tested analytes entering the activ site of our construct.

In addition, for screening of analytes of interest, we concentrated our efforts towards medically relevant and compatibles geometries molecules such as : **9** dopamine, **10** (S)-DOPA, **11** (R)-norepinephrine, **12** (R)-epinephrine, **13** GABA, **14** (S)-glutamic acid, **15** homovanilic acid, **16** DOPAC, **17** (D)-Fructose. (see Figure 3). Finally, we selected *p*-BAPCV \subset bCA and *p*-BAPCV \subset hCAII for screening since best discrimination with the naked eye is obtained with these systems (going from pink to green).

3 Results

The results of the screening showed that *p*-BAPCV (250 μ M) is able to recognize the catechol based neurotransmitters tested (small excess of 10 eq., 2500 μ M) showing no special selectivity (see Figure 1 and Figure 3). **13** GABA or **14** glutamic acid for example were not recognized even with a large excess of analyte (10 or 100 eq.). *p*-BAPCV \subset bCA and *p*-BAPCV \subset hCAII are not able to recognize **17** (D)-fructose even with a large excess (100 eq. compared to the bioreceptor *p*-BAPCV) suggesting that the second coordination sphere plays a critical role in preventing the recognition of the analyte (see Figures 1 and 3). *p*-BAPCV \subset bCA and *p*-BAPCV \subset hCAII recognize preferentially **9** dopamine over **11** (R)-norepinephrine or **12** (R)-epinephrine and other catechol based neurotransmitter even with significant structural similarities suggesting that second coordination sphere plays a Determining role in the selectivity process in the cavity of the protein (see Figure 3). Hence, **15** Homovanilic acid is not recognized by either *p*-BAPCV \subset bCA or *p*-BAPCV \subset hCAII suggesting that the catechol moiety plays a critical role for the recognition of the analyte. *p*-BAPCV \subset bCA II and *p*-BAPCV \subset hCAII follows the same trend in recognition of analytes suggesting that the active sites of both proteins are similar and pursue similar recognition patterns (see Figure 3). **9** dopamine is preferentially recognized over **16** DOPAC suggesting that the functional group at the tail of the neurotransmitter interacts with the second coordination of CA. A positive charge plays a key role in the recognition process (**9** dopamine) over a negative charge (**16** DOPAC).




Figure 2. A) Surface representation sectioning of the X-ray structure **1** *p*-BA inside hCAII (PDB code: 6XVH). [14] Of particular interest is the close lying aminoacid (F-131) to the boronic acid center of the supramolecular construct. **B)** a) Close view of *p*-BA inside hCAII b) statistic table of the crystal structure *p*-BA \subset hCAII **C)** Superposition of hCAII in conjugation with **18** BAD (PDB code: 3MNU) and hCAII with **1** *p*-BA (PDB code: 6XVH). Of particular interest are the aminoacids close to the binding site such as N-62, T-200, V-121, F-131. **D)** a) Proposed mechanisms for the recognition of dopamine inside *p*-BA \subset hCAII, a cataionic NH/ π should occurs with close proximity of F-131 b) Manual docking of dopamine inside the active site of *p*-BA \subset hCAII.

In order to understand the mechanism of selection discriminating the recognition between **9** dopamine and **16** DOPAC we sought to manually dock **9** dopamine inside *p*-BA c hCAII. Upon manual bond rotation we found that F-131 was close lying to the tail of **9** dopamine (see Figure 2). We then realized that the close proximity of an aromatic ring to an amine may lead to an NH/ π interaction that could stabilize the interaction between **9** dopamine and *p*-BA c hCAII. We therefore suggest a mechanism of recognition with an NH/ π interaction F-131 (See Figure 3). It is remarkable to mention the similarity of our artificial system with natural ones. The serine microdomain present in the dopaminergic receptors that interacts with the catechol moiety of dopamine resemble the boronic acid of our receptor. In addition, dopamine is




Figure 3. A) Screening of the synthetic bio-inspired receptor *p*-BAPCV \subset bCA for recognition of neurotransmitters. *p*-BAPCV (250 μ M), outside the protein is orange whereas inside the protein (CA, 250 μ M), the construct (*p*-BAPCV \subset bCA) is pink. Addition of a small excess (2500 μ M, 10 eq. versus sensor) of the analyte to the boronic acid outside of the protein may allow an indicator displacement assay. When *p*-BAPCV (250 μ M) is incorporated inside either **5** bCA or **6** hCA II (250 μ M) forming *p*-BAPCV \subset bCA only **9** dopamine can be fully recognized even with a large excess (0.025 M, 100 eq.) of the other analytes. **B)** Analytes used in the screening of this paper **C)** Absorbance spectra of the screening a) the incorporation of *p*-BAPCV (250 μ M) into bCA (250 μ M) allows a bathochromic shift in colour from $\lambda_{max} = 495$ nm to $\lambda_{max} = 525$ nm. Recognition of (R)-epinephrine **11** (100 eq., 0.025 M) at a concentration 100 eq. higher than **5** *p*-BA allows a poor recognition b) addition of **17** (D)-fructose to *p*-BAPCV \subset bCA doesn't allow an IDA either c) addition of a small excess (10 eq., 2500 μ M) of dopamine **9** to *p*-BAPCV \subset bCA allows an indicator displacement assay d) Decreasing absorbance upon addition of various catechol based analytes such of **9** dopamine (from 1 eq. to 100 eq.) to *p*-BAPCV \subset bCA D) a) Absorbance spectra of *p*-BAPCV \subset bCA in addition with various analytes b) Absorbance of *p*-BAPCV \subset bCA with various analytes at 525 nm.

stabilized in the natural transmembranar receptor via an ionic bond taking advantage of aspartate to the amine moiety. In our system, the stabilisation of dopamine occurs with an NH/π via F-131.

3.2 Test of the best sensor in a complex sample

In order to test our best sensor $p\text{-BAPCV} \subset \text{bCA}$ in real conditions, we decided test the detection of **9** dopamine in human urine. Urine is known to contain traces of **9** dopamine due to metabolic activities in the human body. In a first time, we tested $p\text{-BAPCV}$ in the presence of pure urine from two different persons. Naked-eye detection of **9** dopamine traces was not possible nor any disturbance appeared on the sensor. In a second time we built $p\text{-BAPCV} \subset \text{bCA}$ and tested it against the detection of traces of **9** dopamine in urine. Again, no change in color was observable. In a third time, we spiked urine with **9** dopamine at a concentration of $2500 \mu\text{M}$ and tested $p\text{-BAPCV} \subset \text{bCA}$ for recognition. A concomitant change in color appeared immediately proving the possible determination of **9** dopamine inside complex samples such as human urine. (See supporting information). It allows to conclude that our sensor can be used in complex samples for the detection of **9** dopamine.

4 Conclusions

Bio-molecular systems such as enzymes normally are dedicated to substrate transformations and allows very specific catalytic processes that depends on the composition of the active site. Here we have shown that such an active site can be completely redesigned by the introduction of a specific ligand bearing a functional group. In specific, we have shown that boronic acids can be introduced supramolecularly into a proteic environment and coordinated to indicators allowing specific detection of analytes using a displacement assay, for example dopamine. Despite their limited detection limits, these bio-receptors are distinguished by their easy to assemble, excellent selectivity, commercial disponibility, high modularity and evolvable features. Key to our construction strategy was the reimagination of the active site of carbonic anhydrase within a new structural context; a new boronic acid ligand for coordination of various analytes surrounded by a selective second coordination sphere. This example expands the general use of enzymes transforming them into exquisite biosensors. It could potentially be used for detection of various analytes going from small molecules to microorganisms mimicking natural antibodies.

5 Competing interests

The authors declare no competing interests

6 Contributions

Thibaud Rossel conducted the research, performed the experiments and wrote the manuscript. Bing Zhang produced crystals solved the X-ray structure. Raphael Gobat helped with the crystals production and with solving the X-ray structure.

7 Experimental section

All chemicals were purchased by Sigma Aldrich and used without further purification. hCAII was synthesized by Thomas R. Ward group University of Basel Switzerland.

A typical experiment (such as Figure 3C and D is realized as follows (all solutions are freshly prepared prior to experiment):

25 μL of a 250 μM solution of (*m* or *p*)-BA in HEPES pH = 7.4 100 mM is added to a 25 μL of a 250 μM solution of indicator (PCV or ARS) in a 96 well plate (same buffer). Upon change in color, 25 μL of CA is added to the mix and change in color is observed (same buffer). Addition of 25 μL of analyte allows an indicator displacement assay and a concomitant change in color. The absorbance spectra of the wells are measured in a 96 well plate reader TECAN safire 2 for analysis and comparison.

Acknowledgements

We thank Prof. Camilo Perez as well as Prof. Gilles Gasser for fruitful discussions in this project. We thank Prof. Thomas R. Ward for a loan of a spectrophotometer as well as hCAII. We thank the analytical service (NPAC) of the University of Neuchâtel as well as the Gymnase français de Bienne for providing us lab equipment.

References

- [1] J. M. Beaulieu and R. R. Gainetdinov. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacological reviews*, 63(1):182–217, 2011.
- [2] R. A. Nicoll, R. C. Malenka, and J. A. Kauer. Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system. *Physiological reviews*, 70(2):513–565, 1990.
- [3] X. T. Zhang, G. J. Liu, Z. W. Ning, and G. W. Xing. Boronic acid-based chemical sensors for saccharides. *Carbohydrate research*, 452:129–148, 2017.
- [4] X. Wu, X. X. Chen, and Y. B. Jiang. Recent advances in boronic acid-based optical chemosensors. *Analyst*, 142(9):1403–1414, 2017.
- [5] L. Zhu, Z. Zhong, and E. V. Anslyn. Guidelines in implementing enantioselective indicator-displacement assays for α -hydroxycarboxylates and diols. *Journal of the American Chemical Society*, 127(12):4260–4269, 2005.
- [6] V. M. Krishnamurthy, G. K. Kaufman, A. R. Urbach, I. Gitlin, K. L. Gudiksen, D. B. Weibel, and G. M. Whitesides. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein–ligand binding. *Chemical reviews*, 108(3):946–1051, 2008.
- [7] D. Palm, K. Lang, B. Niggemann, T. L. Drell IV, K. Masur, K. S. Zaenker, and F. Entschladen. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by β -blockers. *International journal of cancer*, 118(11):2744–2749, 2006.
- [8] T. Drell, J. Joseph, K. Lang, B. Niggemann, K. S. Zaenker, and F. Entschladen. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. *Breast cancer research and treatment*, 80(1):63–70, 2003.
- [9] K. Lang, T. L. Drell IV, A. Lindecke, B. Niggemann, C. Kaltschmidt, K. S. Zaenker, and F. Entschladen. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. *International journal of cancer*, 112(2):231–238, 2004.
- [10] E. K. Sloan, S. J. Priceman, B. F. Cox, S. Yu, M. A. Pimentel, V. Tangkanangnukul, and A. K. Sood. The sympathetic nervous system induces a metastatic switch in primary breast cancer. *Cancer research*, 70(18):7042–7052, 2010.
- [11] F. Entschladen, I. V. Drell, L. Theodore, K. Lang, J. Joseph, and K. S. Zaenker. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. *Current pharmaceutical*, 11(3):403–411, 2005.
- [12] A. Barbieri, S. Bimonte, G. Palma, A. Luciano, D. Rea, A. Giudice, and O. De Cobelli. The stress hormone norepinephrine increases migration of prostate cancer cells. *International journal of oncology*, 47:527–534, 2015.
- [13] K. Guo, Q. Ma, L. Wang, H. Hu, J. Li, D. Zhang, and M. Zhang. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. *Oncology reports*, 22(4):825–830, 2009.
- [14] G. De Simone and C. T. Supuran. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics*, 1804(2):404–409, 2010.

- [15] R. A. Wise. Dopamine, learning and motivation. *Nature reviews. neuroscience*, 5(6):483, 2004.
- [16] G. V. Williams and P. Goldman-Rakic. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. *Nature*, 376(6541):572, 1995.
- [17] A. Nieoullon. Dopamine and the regulation of cognition and attention. *Progress in neurobiology*, 67:53–83, 2002.
- [18] R. D. Seidler, J. A. Bernard, T. B. Burutolu, B. W. Fling, M. T. Gordon, J. T. Gwin, and D. B. Lipps. Motor control and aging: links to age-related brain structural, functional, and biochemical effects. *Neuroscience & Biobehavioral Reviews*, 34(5):721–733, 2010.
- [19] R. T. Fremeau, G. E. Duncan, M. G. Fornaretto, A. Dearry, J. A. Gingrich, G. R. Breese, and M. G. Caron. Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. *Proceedings of the national academy of sciences*, 88:3772–3776, 1991.
- [20] K. Lang, T.L. DRELL IV, A. Lindecke, B. Niggemann, C. Kaltschmidt, K. S. Zaenker, and F. Entschladen. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. *International journal of cancer*, 112(2):231–238, 2004.
- [21] L. Zhu and E. V. Anslyn. Facile quantification of enantiomeric excess and concentration with indicator-displacement assays: an example in the analyses of α -hydroxyacids. *Journal of the American Chemical Society*, 126(12):3676–3677, 2004.
- [22] L. Zhu, Z. Zhong, and E. V. Anslyn. Guidelines in implementing enantioselective indicator-displacement assays for α -hydroxycarboxylates and diols. *Journal of the American Chemical Society*, 127(12):4260–4269, 2005.
- [23] J. M. Lehn and A. V. Eliseev. Dynamic combinatorial chemistry. *Science*, 291(5512):2331–2332, 2001.
- [24] J. Bajorath. Integration of virtual and high-throughput screening. *Nature Reviews Drug Discovery*, 1(11):882, 2002.
- [25] F. H. Arnold. Design by directed evolution. *Accounts of chemical research*, 31(3):125–131, 1998.
- [26] G. Springsteen and B. Wang. Alizarin Red S as a general optical reporter for studying the binding of boronic acids with carbohydrates. *Chemical Communications*, 17:1608–1609, 2001.
- [27] M. Y. S. Kalani, N. Vaidehi, S. E. Hall, R. J. Trabanino, P. L. Freddolino, M. A. Kalani, and W. A. Goddard. The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. *Proceedings of the national academy of sciences*, 101:3815–3820, 2004.
- [28] B. E. Collins and E. V. Anslyn. Pattern-Based Peptide Recognition. *Chemistry–A European Journal*, 13(17):4700–4708, 2007.
- [29] Z. Guo, I. Shin, and J. Yoon. Recognition and sensing of various species using boronic acid derivatives. *Chemical Communications*, 48(48):5956–5967, 2012.
- [30] K. E. Secor and T. E. Glass. Selective amine recognition: development of a chemosensor for dopamine and norepinephrine. *Organic letters*, 6(21):3727–3730, 2004.
- [31] Z. Wu, M. Li, H. Fang, and B. Wang. A new boronic acid based fluorescent reporter for catechol. *Bioorganic & medicinal chemistry letters*, 22(23):7179–7182, 2012.
- [32] D. D. Dougherty, A. A. Bonab, T. J. Spencer, S. L. Rauch, B. K. Madras, and A. J. Fischman. Dopamine transporter density in patients with attention deficit hyperactivity disorder. *The Lancet*, 354(9196):2132–2133, 1999.

- [33] C. Bergh, T. Eklund, P. Södersten, and C. Nordin. Altered dopamine function in pathological gambling. *Psychological medicine*, 27(2):473–475, 1997.
- [34] Philip Seeman. Dopamine receptors and the dopamine hypothesis of schizophrenia. *Synapse*, 1(2):133–152, 1987.
- [35] F. E. Albrecht, J. Drago, R. A. Felder, M. P. Printz, G. M. Eisner, J. E. Robillard, D. R. Sibley, H. J. Westphal, and P. A. Jose. Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. *The Journal of clinical investigation*, 97(10):2283–2288, 1996.
- [36] M. B. Spina and G. Cohen. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. *Proceedings of the National Academy of Sciences*, 86(4):1398–1400, 1989.
- [37] M. Moreno-Smith, S. K. Lutgendorf, and A. K. Sood. Impact of stress on cancer metastasis. *Future oncology*, 6(12):1863–1881, 2010.
- [38] K. K. Yang, Z. Wu, and F. H. Arnold. Machine-learning-guided directed evolution for protein engineering. *Nature methods*, 16(8):687–694, 2019.
- [39] G. Li, Y. Dong, and M. T. Reetz. Can machine learning revolutionize directed evolution of selective enzymes? *Advanced Synthesis & Catalysis*, 361(11):2377–2386, 2019.
- [40] Pall Thordarson. Determining association constants from titration experiments in supramolecular chemistry. *Chemical Society Reviews*, 40(3):1305–1323, 2011.
- [41] A. C. Walls, M. A. Tortorici, B. J. Bosch, B. Frenz, P. JM Rottier, F. DiMaio, F. A. Rey, and D. Veasley. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. *Nature*, 531(7592):114–117, 2016.
- [42] C. C. Lai, T. P. Shih, W. C. Ko, H. J. Tang, and P. R. Hsueh. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. *International journal of antimicrobial agents*, page 105924, 2020.
- [43] L. van der Hoek, K. Pyrc, M. F. Jebbink, W. Vermeulen-Oost, R. JM. Berkhout, K. C. Wolthers, P. ME. Wertheim van Dillen, J. Kaandorp, J. Spaargaren, and B. Berkhout. Identification of a new human coronavirus. *Nature medicine*, 10(4):368–373, 2004.
- [44] Danaboyina Ramaiah, Prakash P Neelakandan, Akhil K Nair, and Rekha R Avirah. Functional cyclophanes: promising hosts for optical biomolecular recognition. *Chemical Society Reviews*, 39(11):4158–4168, 2010.
- [45] S. O. Kang, J. M. Llinares, V. W. Day, and Kristin Bowman-James. Cryptand-like anion receptors. *Chemical Society Reviews*, 39(10):3980–4003, 2010.
- [46] D. J. Cram. Cavitands: organic hosts with enforced cavities. *Science*, pages 1177–1183, 1983.
- [47] J. R. Moran, S Karbach, and D. J. Cram. Cavitands: synthetic molecular vessels. *Journal of the American Chemical Society*, 104(21):5826–5828, 1982.
- [48] R. A. Tromans, T. S. Carter, L. Chabanne, M. P. Crump, H. Li, J. V. Matlock, M. G. Orchard, and A. P. Davis. A biomimetic receptor for glucose. *Nature chemistry*, 11(1):52, 2019.
- [49] P. A. Gale, J. L. Sessler, V. Kral, and V. Lynch. Calix [4] pyrroles: Old yet new anion-binding agents. *Journal of the American Chemical Society*, 118(21):5140–5141, 1996.
- [50] W. A. Freeman, W. L. Mock, and N. Y. Shih. Cucurbituril. *Journal of the American Chemical Society*, 103(24):7367–7368, 1981.

- [51] C. J. Pedersen. Cyclic polyethers and their complexes with metal salts. *Journal of the American Chemical Society*, 89(26):7017–7036, 1967.
- [52] C. D. Gutsche and R. Muthukrishnan. Calixarenes. 1. Analysis of the product mixtures produced by the base-catalyzed condensation of formaldehyde with para-substituted phenols. *The Journal of Organic Chemistry*, 43(25):4905–4906, 1978.
- [53] A. Metzger, V. M. Lynch, and E. V. Anslyn. A synthetic receptor selective for citrate. *Angewandte Chemie International Edition in English*, 36(8):862–865, 1997.
- [54] C. Schmuck and M. Schwegmann. A molecular flytrap for the selective binding of citrate and other tricarboxylates in water. *Journal of the American Chemical Society*, 127(10):3373–3379, 2005.
- [55] E. Buhleier, W. Wehner, F. Vögtle, et al. “Cascade”- and “nonskid-chain-like” synthesis of molecular cavity topologies. *Synthesis*, 9(2):155–158, 1978.
- [56] H. Li, M. Eddaoudi, M. O’Keeffe, and O. M. Yaghi. Design and synthesis of an exceptionally stable and highly porous metal-organic framework. *Nature*, 402(6759):276–279, 1999.
- [57] A. Villiers. Sur la transformation de la fécule en dextrine par le ferment butyrique. *Compt. Rend. Fr. Acad. Sci*, 112:435–438, 1891.
- [58] Gregorio Crini. A history of cyclodextrins. *Chemical reviews*, 114(21):10940–10975, 2014.
- [59] T. Rossel and M. Creus. A biomimetic cerium-based biosensor for the direct visual detection of phosphate under physiological conditions. *Chemical Communications*, 55(99):14894–14897, 2019.
- [60] T. Rossel and M. Creus. «La Chimie en Couleurs»: Socially Relevant & Original Research in Chemistry in High Schools Using Modest Resources. *CHIMIA International Journal for Chemistry*, 73(7-8):599–603, 2019.
- [61] G. W. Gokel, W. M. Leevy, and M. E. Weber. Crown ethers: sensors for ions and molecular scaffolds for materials and biological models. *Chemical reviews*, 104(5):2723–2750, 2004.
- [62] W. Kabsch. Xds. *Acta Crystallographica Section D: Biological Crystallography*, 66(2):125–132, 2010.
- [63] A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, and R. J. Read. Phaser crystallographic software. *Journal of applied crystallography*, 40(4):658–674, 2007.
- [64] P. Emsley, B. Lohkamp, W. G. Scott, and K. Cowtan. Features and development of Coot. *Acta Crystallographica Section D: Biological Crystallography*, 66(4):486–501, 2010.
- [65] P. D. Adams, P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L W Hung, G. J. Kapral, R. W-Grosse-Kunstleve, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallographica Section D: Biological Crystallography*, 66(2):213–221, 2010.
- [66] F. W. Monnard, E. S. Nogueira, T. Heinisch, T. Schirmer, and T. R. Ward. Human carbonic anhydrase II as host protein for the creation of artificial metalloenzymes: the asymmetric transfer hydrogenation of imines. *Chemical Science*, 4(8):3269–3274, 2013.
- [67] Serdar Durdagi, Ramin Ekhteiari Salmas, Matthias Stein, Mine Yurtsever, and Philip Seeman. Binding interactions of dopamine and apomorphine in D2High and D2Low states of human dopamine D2 receptor using computational and experimental techniques. *ACS Chemical Neuroscience*, 7(2):185–195, 2016.
- [68] Jie Yin, Kuang-Yui M Chen, Mary J Clark, Mahdi Hijazi, Punita Kumari, Xiao chen Bai, Roger K Sunahara, Patrick Barth, and Daniel M Rosenbaum. Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane. *Nature*, pages 1–5, 2020.

- [69] Anna Di Fiore, Simona Maria Monti, Alessio Innocenti, Jean-Yves Winum, Giuseppina De Simone, and Claudiu T Supuran. Carbonic anhydrase inhibitors: Crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mammalian isoforms I-XV. *Bioorganic & medicinal chemistry letters*, 20(12):3601–3605, 2010.